AptarGroup, Inc. Form 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for AptarGroup, Inc., a Delaware corporation, for the period ended September 30, 2004. The company operates in the packaging components industry, developing, manufacturing, and selling consumer product dispensing systems. Operations are organized into two reportable segments: Dispensing Systems and SeaquistPerfect.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 |
|---|---|---|
| Net Sales | $325.9 million | $953.3 million |
| Operating Income | $37.3 million | $104.4 million |
| Net Income | $25.3 million | $69.3 million |
| Diluted EPS | $0.68 | $1.86 |
| Operating Margin | 11.5% | 11.0% |
| Net Cash Provided by Operations | N/A | $133.4 million |
| Cash and Equivalents | $153.0 million | $153.0 million |
| Total Debt (Short & Long Term) | $194.5 million | $194.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% ($44.6 million) for the quarter and 14% ($118.8 million) for the nine months compared to the prior year. Currency fluctuations contributed approximately $15 million (quarter) and $54 million (nine months) to this growth.
- Profitability: Net income rose 32% for the quarter and 16% for the nine months. Operating margins improved to 11.5% in the quarter from 10.8% in the prior year.
- Cost Pressures: Cost of sales as a percentage of net sales increased to 67.0% (quarter) and 66.7% (nine months) due to rising raw material costs (plastic resin and metal), higher quality-related costs (including a $2.2 million resin issue), and increased sales of lower-margin custom tooling.
- Segment Performance: The Dispensing Systems segment saw EBIT increase 21% to $37.7 million. The SeaquistPerfect segment saw EBIT decrease 7% to $4.3 million due to unfavorable customer mix.
Guidance, Outlook, and Risks
- Outlook: Management expects positive momentum to continue into the fourth quarter, with sales increases across all markets, particularly pharmaceuticals and food/beverage.
- EPS Guidance: Diluted earnings per share for the fourth quarter of 2004 are anticipated to be in the range of $0.57 to $0.62.
- Capital Allocation: The company repurchased 983,000 shares for $42.1 million in the first nine months. A quarterly dividend of $0.15 per share was declared. Capital expenditures for 2004 are estimated at $110 million.
- Risks and Contingencies:
- Foreign Currency: Significant exposure to the Euro; a strengthening dollar has a dilutive effect on results.
- Competition: Continued price pressure, particularly from Asian suppliers in the fragrance/cosmetic and dispensing closure markets.
- Raw Materials: Material costs are expected to continue increasing in the fourth quarter.
- Legal: The company is subject to various lawsuits but does not expect a material adverse effect.
Investor Verification Checklist
- Verify the sustainability of sales growth in the pharmaceutical sector following the inventory reduction by a major customer in late 2003.
- Monitor the ability to pass on rising raw material costs (resin and metal) to customers without losing market share to Asian competitors.
- Assess the impact of the strengthening Euro on future operating margins, given the company's net exporter status from Europe.
- Review the timeline for receiving the $1.5 million in U.S. tax refunds related to R&D expenditures, expected in 2005.
- Confirm the execution of the $110 million capital expenditure plan, specifically regarding the purchase of the manufacturing facility previously leased.